Business Context and Reporting Period
Polaryx Therapeutics, Inc. (PLYX) is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). The company operates as a non-accelerated filer, smaller reporting company, and emerging growth company. This Form 10-K covers the fiscal year ended December 31, 2025. The company recently completed a direct listing on the Nasdaq Capital Market on February 2, 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8.99) million | $(30.36) million |
| Operating Expenses | $7.82 million | $4.35 million |
| Research & Development | $6.27 million | $2.81 million |
| General & Administrative | $1.56 million | $1.54 million |
| Cash and Cash Equivalents (Dec 31) | $5.14 million | $4.62 million |
| Accumulated Deficit | $(99.64) million | $(90.65) million |
| Debt | $0 | $0 |
Note: The 2024 net loss included a non-cash charge of $26.0 million related to the recapitalization of common stock. The 2025 net loss included $1.16 million in direct listing offering costs.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly from $30.4 million in 2024 to $9.0 million in 2025. This improvement is primarily due to the absence of the $26.0 million non-cash recapitalization expense recorded in 2024.
- Increased R&D Spend: Research and development expenses increased by $3.5 million (123%) to $6.3 million, driven by stock-based compensation ($4.3 million) related to a gene therapy patent license, increased CRO services, and consulting fees.
- Capital Raises: The company raised approximately $4.5 million in net proceeds from the issuance of common stock in 2025, compared to $7.2 million in 2024.
- Going Concern: The company continues to report substantial doubt about its ability to continue as a going concern, with cash reserves estimated to fund operations only through the third quarter of 2026.
Guidance, Outlook, and Risks
Outlook and Pipeline
- Lead Candidate (PLX-200): The company is advancing PLX-200, a repurposed oral small molecule, through the SOTERIA Phase 2 basket trial. The FDA granted a "safe to proceed" letter in October 2025. Trial initiation is expected in the second half of 2026.
- Regulatory Pathway: PLX-200 is being pursued via the 505(b)(2) regulatory pathway. The company holds Orphan Drug Designation and Fast Track designation for several indications, including CLN2 and CLN3.
- Other Candidates: PLX-300 (cinnamic acid) is in IND-enabling studies. PLX-100 (combination therapy) and PLX-400 (gene therapy) remain in preclinical stages.
Management Commentary
Management emphasizes the need for substantial additional capital to fund clinical trials and operations. The company does not expect to generate revenue until regulatory approval and commercialization are achieved, which may not occur for several years.
Risks and Contingencies
- Liquidity Risk: The company has an accumulated deficit of nearly $100 million and relies on equity financing. Failure to raise capital could force the suspension of clinical trials.
- Development Risk: Success is heavily dependent on the SOTERIA trial results. Failure of PLX-200 would significantly harm the business, as other pipeline candidates share similar mechanisms of action.
- Related Party Transactions: The company relies on Mstone Partners Healthcare Limited (controlling shareholder) for critical consulting and advisory services, creating potential conflicts of interest.
- Internal Controls: A material weakness in IT general controls regarding segregation of duties was identified in 2024 and remediated in October 2025.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "third quarter of 2026" cash runway estimate given the high burn rate and upcoming Phase 2 trial costs.
- Related Party Fees: Review the terms of the Service Agreement with Mstone, which accounts for a significant portion of operating expenses ($1.6 million in 2025).
- Stock-Based Compensation: Assess the impact of the $4.3 million non-cash R&D expense related to the gene therapy license issuance on future dilution and expense recognition.
- Patent Portfolio: Confirm the status and expiration dates of the licensed patents from Rush University Medical Center, which are critical to the company's IP position.
- Going Concern Status: Monitor for any subsequent equity offerings or strategic partnerships announced to address the substantial doubt regarding the company's ability to continue operations.